EP07.02. The Utility of Postoperative ctDNA Detection in Guiding Adjuvant Therapy for Resectable Stage III Non-small Cell Lung Cancer - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
bolin wang
Meta Tag
Speaker bolin wang
Topic Early-Stage NSCLC: New Technology & Innovations
circulating tumor DNA
adjuvant therapy
resectable stage III non-small cell lung cancer
relapse-free survival
overall survival
prognostic factor
chemotherapy-based ADT
tyrosine kinase inhibitor ADT
Powered By